BDTX insider transaction filings
Black Diamond Therapeutics, Inc. — 35 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen BDTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Campbell Shannon — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Raman Prakash — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Kulkarni Samarth — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Behbahani Ali — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Menzel Garry E — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Dhingra Kapil — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Raman Prakash — Director | Grant/award (A): 7,907 @ $1.66 | EDGAR |
| 2026-06-22 | 4 | Behbahani Ali — Director | Grant/award (A): 8,961 @ $1.66 | EDGAR |
| 2026-03-20 | 4 | Raman Prakash — Director | Grant/award (A): 6,105 @ $2.15 | EDGAR |
| 2026-03-20 | 4 | Behbahani Ali — Director | Grant/award (A): 6,919 @ $2.15 | EDGAR |
| 2026-01-23 | 4 | Jones Erika — SEE REMARKS | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Buck Elizabeth — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Velleca Mark A. — PRESIDENT & CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Yurasov Sergey — CHIEF MEDICAL OFFICER | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Hatzis-Schoch Brent — SEE REMARKS | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Raman Prakash — Director | Grant/award (A): 4,665 @ $2.76 | EDGAR |
| 2025-12-15 | 4 | Behbahani Ali — Director | Grant/award (A): 5,208 @ $2.76 | EDGAR |
| 2025-09-22 | 4 | Raman Prakash — Director | Grant/award (A): 3,843 @ $3.35 | EDGAR |
| 2025-09-22 | 4 | Behbahani Ali — Director | Grant/award (A): 4,291 @ $3.35 | EDGAR |
| 2025-06-20 | 4 | Raman Prakash — Director | Grant/award (A): 5,526 @ $2.33 | EDGAR |
| 2025-06-20 | 4 | Behbahani Ali — Director | Grant/award (A): 6,170 @ $2.33 | EDGAR |
| 2025-06-12 | 4 | Raman Prakash — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Campbell Shannon — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Kulkarni Samarth — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Behbahani Ali — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Menzel Garry E — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Dhingra Kapil — Director | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Raman Prakash — Director | Grant/award (A): 6,848 @ $1.88 | EDGAR |
| 2025-03-21 | 4 | Behbahani Ali — Director | Grant/award (A): 7,646 @ $1.88 | EDGAR |
| 2025-03-20 | 4 | BIOTECH GROWTH N V — 10% owner BB BIOTECH AG — 10% owner | Sale (S): 1,000,000 @ $2.07 · Sale (S): 300,000 @ $1.94 · Sale (S): 1,000,000 @ $2.31 · Sale (S): 2,000,000 @ $2.00 · Sale (S): 400,000 @ $2.09 · Sale (S): 584,292 @ $1.95 · +1 more | EDGAR |
| 2025-01-31 | 4 | Velleca Mark A. — PRESIDENT & CEO, Director | Grant/award (A): 75,000 @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Buck Elizabeth — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 75,000 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Jones Erika — SEE REMARKS | Grant/award (A): 75,000 @ $0 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Yurasov Sergey — CHIEF MEDICAL OFFICER | Grant/award (A): 75,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Hatzis-Schoch Brent — SEE REMARKS | Grant/award (A): 75,000 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Black Diamond Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BDTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →